Prescott Group Capital Management’s Standard BioTools LAB Stock Holding History

Prescott Group Capital Management’s Portfolio LAB Stock Details LAB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-53,236	Closed	-$209K	–	174
2021 Q4	$209K	Buy	+53,236	New	+$249K	0.05%	175
2020 Q4	–	Sell	-97,000	Closed	-$721K	–	108
2020 Q3	$721K	Buy	+97,000	New	+$670K	0.32%	66
2019 Q3	–	Sell	-46,000	Closed	-$567K	–	151
2019 Q2	$567K	Hold	46,000	–	–	0.14%	123
2019 Q1	$611K	Buy	+46,000	New	+$485K	0.13%	122

Other funds holding LAB

ICM

Indaba Capital Management San Francisco, California $33.8M AUM 33.83% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Neuberger Berman Group New York $131B AUM 28.36% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

NIM

Needham Investment Management New York $1.96B AUM 101.23% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

BFM

Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return

Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Prescott Group Capital Management's LAB Position: Q1 2022 in Review

Prescott Group Capital Management sold out of Standard BioTools (LAB) in Q1 2022, closing a stake of 53,236 shares — an estimated $209K sold.

Prescott Group Capital Management first reported a position in LAB in Q1 2019 and held it in 4 quarters. The position peaked at $721K in Q3 2020. 109 funds tracked by Wall St. Rank hold LAB as of Q1 2022.

Prescott Group Capital Management reported no remaining Standard BioTools position as of Q1 2022 after selling out during the quarter.
Prescott Group Capital Management sold 53,236 Standard BioTools shares in Q1 2022, an estimated $209K.
Prescott Group Capital Management first reported a position in Standard BioTools in Q1 2019 and held it in 4 quarters.
Prescott Group Capital Management's Standard BioTools position peaked at $721K in Q3 2020.
109 funds tracked by Wall St. Rank held Standard BioTools as of Q1 2022.

Based on Prescott Group Capital Management's 13F filing for Q1 2022, filed 10 May 2022.